Impact of IgG subclass on monoclonal antibody developability
IgG-based monoclonal antibody therapeutics, which are mainly IgG1, IgG2, and IgG4 subclasses or related variants, have dominated the biotherapeutics field for decades. Multiple laboratories have reported that the IgG subclasses possess different molecular characteristics that can affect their developability. For example, IgG1, the most popular IgG subclass for therapeutics, is known to have a characteristic degradation pathway related to its hinge fragility. However, there remains a paucity of studies that systematically evaluate the IgG subclasses on manufacturability and long-term stability. We thus conducted a systematic study of 12 mAbs derived from three sets of unrelated variable regions, each cloned into IgG1, an IgG1 variant with diminished effector functions, IgG2, and a stabilized IgG4 variant with further reduced FcγR interaction, to evaluate the impact of IgG subclass on manufacturability and high concentration stability in a common formulation buffer matrix. Our evaluation included Chinese hamster ovary cell productivity, host cell protein removal efficiency, N-linked glycan structure at the conserved N297 Fc position, solution appearance at high concentration, and aggregate growth, fragmentation, charge variant profile change, and post-translational modification upon thermal stress conditions or long-term storage at refrigerated temperature. Our results elucidated molecular attributes that are common to all IgG subclasses, as well as those that are unique to certain Fc domains, providing new insight into the effects of IgG subclass on antibody manufacturability and stability. These learnings can be used to enable a balanced decision on IgG subclass selection for therapeutic antibodies and aid in acceleration of their product development process.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
mAbs - 15(2023), 1 vom: 03. Jan., Seite 2191302 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cain, Paul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.03.2023 Date Revised 12.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/19420862.2023.2191302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354503677 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354503677 | ||
| 003 | DE-627 | ||
| 005 | 20231226062350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19420862.2023.2191302 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354503677 | ||
| 035 | |a (NLM)36945111 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cain, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of IgG subclass on monoclonal antibody developability |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IgG-based monoclonal antibody therapeutics, which are mainly IgG1, IgG2, and IgG4 subclasses or related variants, have dominated the biotherapeutics field for decades. Multiple laboratories have reported that the IgG subclasses possess different molecular characteristics that can affect their developability. For example, IgG1, the most popular IgG subclass for therapeutics, is known to have a characteristic degradation pathway related to its hinge fragility. However, there remains a paucity of studies that systematically evaluate the IgG subclasses on manufacturability and long-term stability. We thus conducted a systematic study of 12 mAbs derived from three sets of unrelated variable regions, each cloned into IgG1, an IgG1 variant with diminished effector functions, IgG2, and a stabilized IgG4 variant with further reduced FcγR interaction, to evaluate the impact of IgG subclass on manufacturability and high concentration stability in a common formulation buffer matrix. Our evaluation included Chinese hamster ovary cell productivity, host cell protein removal efficiency, N-linked glycan structure at the conserved N297 Fc position, solution appearance at high concentration, and aggregate growth, fragmentation, charge variant profile change, and post-translational modification upon thermal stress conditions or long-term storage at refrigerated temperature. Our results elucidated molecular attributes that are common to all IgG subclasses, as well as those that are unique to certain Fc domains, providing new insight into the effects of IgG subclass on antibody manufacturability and stability. These learnings can be used to enable a balanced decision on IgG subclass selection for therapeutic antibodies and aid in acceleration of their product development process | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aggregates | |
| 650 | 4 | |a IgG subclass | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a charge variants | |
| 650 | 4 | |a developability | |
| 650 | 4 | |a fragments | |
| 650 | 4 | |a host cell protein | |
| 650 | 4 | |a post-translational modification | |
| 650 | 4 | |a productivity | |
| 650 | 4 | |a stability | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Huang, Lihua |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Anguiano, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Yiqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mAbs |d 2009 |g 15(2023), 1 vom: 03. Jan., Seite 2191302 |w (DE-627)NLM194097110 |x 1942-0870 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:03 |g month:01 |g pages:2191302 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/19420862.2023.2191302 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 03 |c 01 |h 2191302 | ||